Nov 13 (Reuters) - The U.S. Food and Drug Administration has approved Kura Oncology's KURA.O drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))